Authors


Mark Lewis, MD

Latest:

Research Considerations for ctDNA Testing in Colorectal Cancer

Panelists discuss how research on circulating tumor DNA (ctDNA) testing in colorectal cancer requires careful consideration of standardized collection protocols, analytical validation, clinical utility assessment, integration with existing biomarkers, and longitudinal monitoring to establish its role in personalized treatment decision-making.


Errol J. Philip, PhD

Latest:

Psycho-Oncology and the Relevance of a Biopsychosocial Screening Program

Routine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.




Paolo Scollo, MD

Latest:

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy

A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.


Gevorg Aloyan, MD, PhD

Latest:

How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.


Sameh Gaballa, MD

Latest:

Unmet Needs and Looking Ahead in Follicular Lymphoma

Sameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.


Daniel Walden, MD

Latest:

The Future of BRAF-Mutant mCRC Management

Christina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting.


Amy Comander, MD

Latest:

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.


Geoffrey A. Talmon, MD

Latest:

Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive

ABSTRACT Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. They commonly present with nonspecific symptoms and thus are often discovered incidentally. They are best identified by CT scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. Several risk stratification classification systems have been developed based on tumor size, mitotic rate, location, and perforation. Traditional chemotherapy and radiation therapy have been very ineffective, making surgery the mainstay of treatment. The discovery of mutations associated with these tumors has revolutionized the treatment approach. Imatinib mesylate, a selective tyrosine kinase receptor inhibitor, used as adjuvant or neoadjuvant therapy, has greatly improved the morbidity and mortality associated with GISTs. As the survival of patients has increased with the long-term use of targeted therapies, quality-of-life issues now have become much more relevant and have come to the forefront of care. We present a young woman who was successfully treated for GIST but now faces associated long-term adverse effects of imatinib, including the challenge of preserving fertility and the potential for childbearing.


Lauren Welch, MSN, NP-C, AOCNP

Latest:

Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care

Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.



Mazyar Shadman, MD, MPH

Latest:

Future Directions and Key Insights in LBCL Treatment

Experts discuss future directions and key insights in treating large B-cell lymphoma (LBCL).


Ioannis Vamvakaris, MD, PhD, MSc

Latest:

Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs

Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.


Veronica B. Decker, DNP, MBA, APRN, PMHCNS-BC

Latest:

Caring for Patients With Serious Mental Illness: Guide for the Oncology Clinician

Veronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.






Asim Farooq, MD

Latest:

From Challenges to Solutions: Ensuring Timely and Effective Molecular Testing in Ovarian Cancer

Panelists discuss how overcoming barriers to molecular testing in ovarian cancer requires addressing logistical challenges like tissue availability and external pathology coordination, managing financial constraints through institutional support and low-cost options, and enhancing patient communication by clearly explaining how testing creates a personalized treatment roadmap that empowers patients to pursue tailored therapies based on their tumor's genetic and molecular profile.





Philip J. Gold, MD

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.




Gauhar Sultan, MMBS, FCPS

Latest:

Squamous Cell Carcinoma of the Kidney: A Large Case Series

Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.